FDA approves Eli Lilly's Alzheimer’s drug that slows memory decline

The Food and Drug Administration approved a new Alzheimer’s drug from Eli Lilly that has been shown in clinical trials to modestly slow a decline in memory and thinking abilities in people with the disease, the drugmaker said Tuesday. The drug donanemab, which will be sold under the brand name Kisunla, is a monoclonal antibody infusion given every four weeks. The FDA cleared the drug for use in adults with mild cognitive impairment or early Alzheimer’s disease, the drugmaker said.

Like other drugs in its class, Kisunla also comes with potentially life-threatening side effects, which include brain swelling and brain bleeding. Although most cases identified in the trial were mild, ​​three deaths were linked to the drug, according to the FDA. Kisunla is now the second Alzheimer’s drug of its kind approved, behind Leqmebi. A third drug — Biogen’s Aduhelm — was taken off the market earlier this year.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA advisors recommend Eli Lilly Alzheimer’s drug that slows diseaseEli Lilly's new Alzheimer's drug, donanemab, received approval from an advisory panel for the FDA. The full agency is expected to approve the drug by spring.
Source: dcexaminer - 🏆 6. / 94 Read more »

Alzheimer’s drug from Eli Lilly wins backing of FDA committeeAn advisory committee to the Food and Drug Administration found the drug was safe and effective at slowing the progression of the disease, setting the stage for the agency to approve it.
Source: washingtonpost - 🏆 95. / 72 Read more »

FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Source: KSLcom - 🏆 549. / 51 Read more »

FDA approves new Alzheimer's treatment, donanemab from Eli LillyFDA approval of the new Alzheimer's treatment, which will be branded as Kisunla, follows years of setbacks.
Source: CBSNews - 🏆 87. / 68 Read more »